BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 22371455)

  • 21. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
    Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
    Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
    Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
    Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
    Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
    EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
    J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of SOCS3 exhibits preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Nomura S; Osaki T; Lee CM; Mizuguchi H; Takahashi T; Ripley B; Okumura M; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2011 Aug; 129(4):1005-17. PubMed ID: 20949562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.
    Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
    Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
    Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
    Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesothelin promotes invasion and metastasis in breast cancer cells.
    Wang Y; Wang L; Li D; Wang HB; Chen QF
    J Int Med Res; 2012; 40(6):2109-16. PubMed ID: 23321167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas.
    Shukla A; Hillegass JM; MacPherson MB; Beuschel SL; Vacek PM; Butnor KJ; Pass HI; Carbone M; Testa JR; Heintz NH; Mossman BT
    Int J Cancer; 2011 Sep; 129(5):1075-86. PubMed ID: 21710492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.
    Mehner C; Hockla A; Miller E; Ran S; Radisky DC; Radisky ES
    Oncotarget; 2014 May; 5(9):2736-49. PubMed ID: 24811362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
    Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
    Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
    Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
    Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.
    Takeuchi S; Fukuda K; Yamada T; Arai S; Takagi S; Ishii G; Ochiai A; Iwakiri S; Itoi K; Uehara H; Nishihara H; Fujita N; Yano S
    Cancer Sci; 2017 Apr; 108(4):696-703. PubMed ID: 28182302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
    Inaguma S; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Kasai K; Miettinen M; Ikeda H
    J Pathol; 2020 Feb; 250(2):205-216. PubMed ID: 31639216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K
    Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.
    Sapede C; Gauvrit A; Barbieux I; Padieu M; Cellerin L; Sagan C; Scherpereel A; Dabouis G; Grégoire M
    Cancer Sci; 2008 Mar; 99(3):590-4. PubMed ID: 18167128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.